Therapeutic drug monitoring of lacosamide as add-on treatment in a neonate with therapy-resistant epilepsy due to SCN2A mutation: a case report Authors: M. Slikkerveer, M. C. Hutten, S. Klinkenberg, A. C. S. Knijnenburg Published: 2026 ABSTRACT BackgroundLacosamide is registered for the treatment of (partial-onset) seizures in adults and children > 2 years of age, with a recommended maximum dose of 12 mg kg-1 in two doses. It is generally well tolerated. The use of lacosamide in neonates is off-label. We present the first case of a neonatal patient with refractory epilepsy who was started on lacosamide with monitoring of serial serum levels.Case presentationWe present a case of a prematurely (33 weeks) born Dutch, male neonate with refractory seizures despite multiple anti-epileptic drugs due to a de novo SCN2A mutation. Lacosamide was added, and serial serum trough levels were measured to optimize the dose. Based on the available literature, the dose needed to achieve a therapeutic serum trough level in our patient was much higher than expected, with a dose of 22 mg kg-1 in 4 doses. No side effects were observed.ConclusionIn specific cases in the neonatal population, lacosamide is safe and well tolerated and should be considered as a treatment option under strict surveillance of serum trough levels and cardiac monitoring. Higher doses might be needed to achieve a therapeutic serum trough level. Further research is needed to generalize these results and develop adjusted dose guidelines in the neonatal population. Background Lacosamide(LCM) was licensed in 2008 as antiseizure medication (ASM). It is indicated as monotherapy and adjuvant therapy for the treatment of partial-onset seizures, with or without secondary generalization in adults, adolescents, and children from 2 years of age and the adjuvant treatment of primary generalized tonic–clonic seizures in adults, adolescents, and children from 4 years of age with idiopathic generalized epilepsy [1]. LCM is rapidly and completely absorbed after oral administration. The oral biological availability of LCM is approximately 100%. After oral administration, the plasma peak concentration is achieved after 0.5–4 h. The volume of distribution is about 0.6 l kg-1, and less than 15% of LCM is bound to plasma proteins [1, 2]. 95% of LCM and its metabolites are eliminated renally, 40% in unchanged form. 60% is metabolized in the liver by demethylation, primarily by CYP2C19, but CYP3A4 and CYP2C9 may also be involved to form the inactive metabolite O-desmethyl lacosamide (30%) together with other unidentified metabolites (30%). The half-life in adults is around 13 h [1, 2]. It has a low potential for clinically relevant pharmacokinetic drug–drug interactions, but systemic exposure may be reduced by enzyme-inducing anti-epileptics (carbamazepine, phenytoin, phenobarbital) [1, 3]. The reference range for LCM concentration in plasma is 10–20 mg L-1 [4]. Dose advise for children ≥ 2 years is to start with 2 mg kg-1 per day and to gradually increase the dose to an optimum response with a maximum of 12 mg kg-1 per day in 2 doses. [1] Because the pharmacokinetics of LCM are linear and constant over time, with low intra- and intersubject variability and minimal drug interactions, therapeutic drug monitoring (TDM) is normally not indicated. LCM is not registered for neonates, so there is less (pharmacokinetic) information on the use of LCM in neonates. However, case reports showed a favorable outcome with seizure reduction in neonates with a SCN2a mutation treated with LCM [5]. In the neonatal population, there are also case reports using LCM in super-refractory status epilepticus [6]. Here, we report the first case of a premature neonate, with treatment-resistant epilepsy, who was treated with LCM, for whom we measured serial serum trough concentrations to optimize dosage. Case presentation We present a Dutch boy, born prematurely at 33 weeks gestational age, after an uncomplicated pregnancy. Apgar scores were 3–7 and 8 after 1–5–10 min, respectively. He was admitted to the neonatal care unit, where he received respiratory support with Continuous Positive Airway Pressure (CPAP). Three days after birth, seizures developed, with episodic clonic activity of arms and legs, and frequent apneas with bradycardia which could not be attributed to his late prematurity. Amplitude-integrated electroencephalography was started, and continuous convulsive activity was observed and confirmed on an electroencephalogram (EEG). Respiratory support was intensified with mechanical ventilation. Phenobarbital, levetiracetam, and pyridoxine were started consecutively during the first days (maximum dosage for each drug: phenobarbital 6 mg kg-1 per day, levetiracetam 60 mg kg-1 per day, pyridoxine 20 mg kg −1 per day). However, the seizures were refractory to ASM. Continuous midazolam perfusion was started, but discontinued due to persisting seizures (maximum dosage 0,6mg kg-1 per hour). Consequently, carbamazepine, lidocaine, and nitrazepam were started (maximum dosage carbamazepine 36 mg kg-1 per day, lidocaine 6 mg kg-1 per hour, nitrazepam 1,1mg kg-1 per day). However, seizures still persisted with a different semiology consisting of orofacial dyskinesia, tonic seizures, clonic seizures, and myoclonia, sometimes including apneic spells. EEG showed a burst suppression pattern with high-voltage sharp activity. The myoclonic movements did not correlate with electroencephalographic activity. Genetic workup showed a probable pathogenic de novo variant in the Sodium voltage-gated channel alpha subunit 2 (SCN2a) gene. SCN2A gene mutations are associated with neonatal and infantile epilepsy and epileptic encephalopathy. SCN2A mutation with early neonatal seizures are usually the result of a gain of function mutation at this age [7, 8]. Commonly effective anti-epileptic drugs in this gain of function mutation are sodium channel blockers, for example, carbamazepine and phenytoin [7]. With refractory seizures despite multiple ASM, phenytoin was started and continuous midazolam was restarted; however, the seizures persisted. Case reports show a favorable outcome with seizure reduction in neonates with a SCN2a mutation treated with LCM [5]. In the pediatric population LCM is used in status epilepticus [9]. In the neonatal population, there are also case reports using LCM in super-refractory status epilepticus [6]. Because of super-refractory epilepsy not responding to standard treatments, we decided to start LCM on day 27. The patient was still in the NICU and cardiac rhythm was monitored, because of reported prolonged QT intervals. Frequent serum trough levels of LCM were performed because of possible interactions and dosage guidelines only starting from the age of two. Since no serum trough reference values are available for neonates, we decided to use the adult reference values (10–20 mg L-1) from Patsanos et al. [4]. The starting dosage was 10 mg kg-1 per day in 2 doses, resulting in a trough level of 6.4mg l-1. LCM was switched to 10 mg kg-1 per day in 3 doses, resulting in 5.4mg l-1 trough level after 3 days. Dosage was raised to 15 mg kg-1 per day in 3 doses. The serum trough level after 2 days was 4.4mg l-1. It appeared that the patient cleared the LCM quickly. Therefore, it was decided to increase the dose to 20 mg kg-1 per day 4 times a day and to calculate the half-life. 4 h (11.6mg l-1) and 6 h (8.9mg l-1) after administration levels were measured, resulting in a calculated half-life of 5.2 h. 4 days after raising the dosage the trough level was 9.1mg l-1. The dosage was raised to 22 mg kg-1 per day 4 times a day, with a trough level of 15.9 mg l-1 after 2 days. A week later the trough level was 9.7mg l-1 and this remained stable with a trough level of 10.3mg l–1 2 weeks later. Figure 1 shows an overview of serum trough levels and corresponding dose. No apparent side effects occurred; however, he was still deeply sedated with the need for mechanical ventilation with the combination of ASM. During treatment with LCM, clinical and electroencephalographic seizures remitted. We were able to wean the midazolam and lower nitrazepam, with a beneficial effect on the patients’ consciousness. After decreasing the benzodiazepines, vigabatrin was added. We were able to wean the nitrazepam, phenytoin, vigabatrin and phenobarbital during follow-up. Seizure control is reached since the age of 5 months with the combination of LCS and carbamazepine both in 3 doses per day nowadays. He has a developmental delay that is commonly observed in patients with this underlying mutation.Fig. 1Overview of serum trough levels in mg/l and lacosamide dose Overview of serum trough levels in mg/l and lacosamide dose Discussion and conclusions To the best of our knowledge, this is the first case report reporting serial serum trough concentrations of LCM in a preterm neonate with successful seizure reduction. We based this decision on multiple case reports and case series; however, we could not find dosage recommendations and therapeutic serum trough levels in this population in the current literature and decided to start LCM only under frequent measurements of serum trough levels. One case report described a term neonate (15 days old), where they measured only one serum trough level of 1.5mg l-1 after a bolus dose of 8 mg kg-1, followed by a dose of 5 mg kg-1 every twelve hours [6]. In another case series that included 38 neonates, LCM was generally well tolerated, but there was a large difference in dosing of LCM, with reported doses between 1.42 and 10 mg kg-1 [10]. Very recently, after our patient presented on the neonatal care unit, Fong et al. reported a retrospective multicenter cohort study including 714 pediatric patients (686 children and 28 neonates). They reported a low percentage of adverse events in children (1.5%), with no adverse events reported in neonates. Adverse events included rash (n = 3, 0.4%), somnolence (n = 2, 0.3%), bradycardia, prolonged QT interval, pancreatitis, vomiting, and nystagmus (n = 1, 0.1% each). For neonates, the median total dose on the index day was 2.0 mg kg-1 for the recommended dose cohort compared to 6.3 mg kg-1 for the high dose cohort. Serum trough levels and gestational age of the included neonates were not reported [11]. Based on the available literature, the dose needed to achieve a therapeutic serum trough level in our patient was much higher than expected and pharmacokinetics appear to be significantly different in our patient. We have considered a number of possible explanations; Glomerular filtration rate (GFR) is low at birth, with a value close to 20 ml per min per 1.73m2 in term neonates, and this may be even lower in premature infants. After birth, GFR develops rapidly, its value doubling within the first 5 days after birth. Then, the GFR rises gradually to 60 ml per min at 4 weeks, and eventually, it increases steadily until it reaches adult values around the age of 12 months [12, 13]. In our case, the half-life was significantly reduced, with a calculated half-life of 5.5 h compared to 13 h reported in the literature, while you would expect that with a lower GFR, the half-life would be longer. We measured creatinine/serum twice in the period he was admitted, both were normal. Another possible explanation is an interaction with carbamazepine, phenytoin, and phenobarbital. These enzyme-inducing ASMs increase the elimination of LCM and decrease the plasma LCM concentrations by 17% in pediatric patients [1]. In a study including both children and adults (age 1.6–80 y), even a reduction of 30–40% of LCM serum trough concentration was measured in combination with enzyme-inducing ASM [14]. Another possible explanation is the relatively high body water content and lower fat content in neonates, making the volume of distribution of the water-soluble LCM higher in neonates. This results in the need for larger doses to reach therapeutic concentrations and may increase the clearance of LCM and reduce the half-life in neonates. [15–17] Weight-dependent half-life of LCM in children is also seen. Literature reports a half-life in children over 4 years of age of 7.4 h in children weighing 11 kg, while children weighing 28.9 kg have a half-life of 10.6 h, and children weighing 70 kg have a half-life of 14.8 h. Body composition and the use of co-medication were not described [15]. With the addition of LCM, we did not see any side effects. However, he was still deeply sedated with the need for mechanical ventilation with the combination of ASM. We were able to wean the midazolam and lower nitrazepam, with a beneficial effect on the patients’ consciousness. Information about long-term side effects are currently not known. In conclusion, in specific cases in the neonatal population, lacosamide is safe and well tolerated and should be considered as a treatment option under strict surveillance of serum trough levels and cardiac monitoring. Higher doses might be needed to achieve a therapeutic serum trough level. Further research is needed to generalize these results and develop adjusted dose guidelines in the neonatal population.